1887

Chapter 20 : Sequelae of Chronic Viral Hepatitis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Sequelae of Chronic Viral Hepatitis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815486/9781555814304_Chap20-1.gif /docserver/preview/fulltext/10.1128/9781555815486/9781555814304_Chap20-2.gif

Abstract:

This chapter reviews the natural history of chronic viral hepatitis, focuses on pathogenesis, and outlines the characteristics of the complications and the management. Hepatitis B virus (HBV) is recognized as one of a family of animal viruses called hepadnaviruses and is classified as hepadnavirus type 1. The aims of treatment for chronic HBV (CHB) are to achieve sustained suppression of HBV replication and remission of liver disease. The ultimate goal is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC). The current standard of care is combination pegylated interferon (PEG) and weight-based ribavirin (RBV). Viral clearance needs to be achieved prior to the development of cirrhosis to have a marked impact on the development of HCC. There is a single prospective population-based study of the risk of HCC in patients with hepatitis C. In this study of 12,008 men, being anti-HCV positive conferred a 20-fold increased risk of HCC compared to being anti-HCV negative. Liver transplantation remains the most effective treatment because it removes the tumor and eliminates the risk for new tumors, and it prevents liver failure. Another analysis showed that spontaneous reductions over time in HBV DNA levels from 300 to 100,000 copies/ml to <300 copies/ml, after controlling for other risks, eliminated the additional risk of developing HCC, based on the baseline HBV DNA level.

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20

Key Concept Ranking

Viral Hepatitis
0.43926945
Hepatocellular Carcinoma
0.43046013
Highly Active Antiretroviral Therapy
0.4010919
0.43926945
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

Outcome of HBV infection based on age at time of infection. Solid line, risk of chronicity; dashed line, percentage presenting with symptoms.

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Epidemiology of HCV infection: 170 million (M) people are chronically infected with HCV ( ).

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Genotype prevalence of HCV varies according to geographic region ( ).

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815486.ch20
1. Alter, M. J.,, D. Kruszon-Moran,, O. V. Nainan,, G. M. McQuillan,, F. Gao,, L. A. Moyer,, R. A. Kaslow, and, H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556562.
2. Beasley, R. P. 1982. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma. Hepatology 2(Suppl):21S26S.
3. Beasley, R. P.,, L. Y. Hwang,, C. C. Lin, and, C. S. Chien. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:11291133.
4. Befeler, A. S.,, and A. M. Di Bisceglie. 2002. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 55:16091619.
5. Benvegnù, L.,, M. Gios,, S. Boccato, and, A. Alberti. 2004. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complication. Gut 53:744749.
6. Bruix, J.,, and M. Sherman. 2005. Management of hepatocellular carcinoma. Hepatology 42:12081236.
7. Bruno, S.,, T. Stroffolini,, M. Colombo,, S. Bollani,, L. Benvegnù,, G. Mazzella,, A. Ascione,, T. Santantonio,, F. Piccinino,, P. Andreone,, A. Mangia,, G. B. Gaeta,, M. Persico,, S. Fagiuoli,, P. L. Almasio, and Italian Association of the Study of the Liver Disease (AISF). 2007. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579587.
8. Cardoso, A. C.,, R. Moucari,, N. Boyer,, T. Asselah,, A. Laatar,, M.-P. Ripault,, M. Martinot-Peignoux,, S. Maylin,, P. Bedossa, and, P. Marcellin. 2007. Positive impact of antiviral therapy on the long term outcome of chronic hepatitis C patients with cirrhosis. Hepatology 46(Suppl. 1):346A. (Abstract.)
9. Reference deleted.
10. Chen, C.-F.,, H.-I. Yang,, U. Iloeje,, C.-F. Chen,, H.-I. Yang,, U. Iloeje,, J. Su,, C.-L. Jen,, S.-L. You, and, C.-J. Chen. 2007. Changes in serum HBV DNA level using a trajectory model predict the risk of HCC in chronic hepatitis B patients: the REVEAL-HBV study. Hepatology 46(Suppl. 1):639A. (Abstract.)
11. Chen, C.-J.,, H.-I. Yang,, J. Su,, C. L. Jen,, S. L. You,, S. N. Lu,, G. T. Huang,, U. H. Iloeje, and the REVEAL-HBV Study Group. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:6573.
12. Di Bisceglie, A. M.,, M. L. Shiffman,, G. T. Everson,, K. L. Lindsay,, J. E. Everhart,, E. C. Wright,, W. M. Lee,, A. S. Lok,, H. Bonkovsky,, T. R. Morgan,, J. L. Dienstag,, M. Ghany,, C. Morishima, and, K. K. Snow. 2007. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 46(Suppl. 1):80A. (Abstract.)
13. Dienstag, J. L.,, and K. J. Isselbacher. 2005. Acute viral hepatitis, p. 1882–1937. In D. L. Casper,, A. S. Fauci,, L. Longo,, E. Braunwald,, S. L. Hauser, and, J. L. Jameson (ed.), Harrison’s Principles of Internal Medicine. McGraw-Hill, New York, NY.
14. El-Serag, H. B.,, and A. C. Mason. 1999. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340:745750.
15. Fattovich, G.,, T. Stroffolini,, I. Zagni, and, F. Donato. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(Suppl. 1):S35S50.
16. Frey, S. E.,, G. J. Gorse,, A. M. DiBisceglie,, D. Rosa,, Z. Stamataki,, J. McKeating,, R. Ray,, S. Coates,, V. Schultze,, S. Abrignan,, M. Houghton,, H. Hill, and, R. B. Belshe. 2006. A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002). J. Clin. Virol. 36(Suppl. 2):S5. (Abstract.)
17. Fried, M. W.,, M. L. Shiffman,, K. R. Reddy,, C. Smith,, G. Marinos,, F. L. Gonçales, Jr.,, D. Häussinger,, M. Diago,, G. Carosi,, D. Dhumeaux,, A. Craxi,, A. Lin,, J. Hoffman, and, J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975982.
18. Hadziyannis, S. J.,, H. Sette, Jr.,, T. R. Morgan,, V. Balan,, M. Diago,, P. Marcellin,, G. Ramadori,, H. Bodenheimer, Jr.,, D. Bernstein,, M. Rizzetto,, S. Zeuzem,, P. J. Pockros,, A. Lin,, A. M. Ackrill, and the PEGASYS International Study Group. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346355.
19. Heathcote, J. E. 2007. Antiviral therapy: chronic hepatitis C. J. Viral Hepat. 14(Suppl. 1):8288.
20. Inchauspé, G.,, and M. L. Michel. 2007. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat. 14(Suppl. 1):97103
21. Jensen, D. M.,, T. R. Morgan,, P. Marcellin,, P. J. Pockros,, K. R. Reddy,, S. J. Hadziyannis,, P. Ferenci,, A. M. Ackrill, and, B. Willems. 2006. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954960.
22. Lai, C.-L.,, and M.-F. Yuen. 2007. The natural history of chronic hepatitis B. J. Viral Hepat. 14(Suppl. 1):610.
23. Liaw, Y. F.,, D. I. Tai,, C. M. Chu, and, T. J. Chen. 1988. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8:493496.
24. Liaw, Y. F.,, J. J. Sung,, W. C. Chow,, G. Farrell,, C. Z. Lee,, H. Yuen,, T. Tanwandee,, O. M. Tao,, K. Shue,, O. N. Keene,, J. S. Dixon,, D. F. Gray,, J. Sabbat, and the Cirrhosis Asian Lamivudine Multicentre Study Group. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:15211531.
25. Liaw, Y. F.,, C. M. Lee,, R. N. Chien, and, C. T. Yeh. 2006. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J. Viral Hepat. 13:250255.
26. Llovet, J.,, S. Ricci,, V. Mazzaferro,, P. Hilgard,, E. Gane,, J. F. Blanc,, A. C. de Oliveira,, A. Santoro,, J. L. Raoul,, A. Forner,, M. Schwartz,, C. Porta,, S. Zeuzem,, L. Bolondi,, T. F. Greten,, P. R. Galle,, J. F. Seitz,, I. Borbath,, D. Häussinger,, T. Giannaris,, M. Shan,, M. Moscovici,, D. Voliotis,, J. Bruix, and the SHARP Investigators Study Group. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:37890.
27. Lok, A. S.,, and B. J. McMahon. 2007. Chronic hepatitis B. Hepatology 45:507539.
28. Mancini-Bourgine, M.,, H. Fontaine,, D. Scott-Algara,, S. Pol,, C. Brechot, and, M. L. Michel. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874882.
29. Reference deleted.
30. Manno, M.,, C. Camma,, F. Schepis,, F. Bassi,, R. Gelmini,, F. Giannini,, F. Miselli,, A. Grottola,, I. Ferretti,, C. Vecchi,, M. De Palma, and, E. Villa. 2004. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 127:756763.
31. Manns, M. P.,, J. G. McHutchison,, S. C. Gordon,, V. K. Rustgi,, M. Shiffman,, R. Reindollar,, Z. D. Goodman,, K. Koury,, M. Ling, and, J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958965.
32. Manos, M.,, and R. C. Murphy. 2007. Viral hepatitis registry, Kaiser Permanente Northern California, Oakland, California. Trends in the incidence and etiology of hepatocellular carcinoma in a managed care population: The roles of viral hepatitis and fatty liver disease. Hepatology 46(Suppl. 1):400A. (Abstract.).
33. McHutchison, J. G.,, G. T. Everson,, S. Gordon,, I. Jacobson,, R. Kauffman,, L. McNair, and, A. Muir. 2007. Results of an interim analysis of a phase 2 study of telaprevir (VX 950) with peginterferon alpha 2a and ribavirin in previously untreated subjects with hepatitis C. J. Hepatol. 42(Suppl. 1):S296. (Abstract.)
34. Nevens, F.,, T. Roskams,, H. Van Vlierberghe,, Y. Horsmans,, D. Sprengers,, A. Elewaut,, V. Desmet,, G. Leroux-Roels,, E. Quinaux,, E. Depla,, S. Dincq,, C. Vander Stichele,, G. Maertens, and, F. Hulstaert. 2003. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38:12891296.
35. Niederau, C.,, T. Heintges,, S. Lange,, G. Goldmann,, C. M. Niederau,, L. Mohr,, D. Häussinger. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334:14221427.
36. Poynard, T.,, V. Ratziu,, F. Charlotte,, Z. Goodman,, J. McHutchison, and, J. Albrecht. 2001. Rates and risk factors of liver cirrhosis progression in patients with chronic hepatitis C. J. Hepatol. 34:730739.
37. Reference deleted.
38. Roberts, S.,, G. Cooksley,, D. Shaw,, H. K. Berns,, M. T. Brandl,, S. H. Fettner,, G. Hill,, D. Ipe,, K. Klumpp,, M. Mannino,, E. O’Mara,, Y. Tuo, and, C. B. Washington. 2006. Interim results of a multiple ascending dose study of R1 626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J. Hepatol. 44(Suppl. 2):S269. (Abstract.)
39. Rodriguez-Luna, H.,, and H. E. Vargas. 2005. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl. 11:479489.
40. Romero-Marrero, C. J.,, S. Fu,, V. Thyagarajan,, R. J. Fontana,, A. S. Lok,, S. Pelletier, and, J. A. Marrero. 2007. Predictors of dropout from transplant waiting list among patients listed for hepatocellular carcinoma using the UNOS/OPTN Database. Hepatology 46(Suppl. 1):241A. (Abstract.)
41. Ruiz, J. D.,, F. Molitor,, R. K. Sun,, J. Mikanda,, M. Facer,, J. M. Colford, Jr.,, G. W. Rutherford, and, M. S. Ascher. 1999. Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West. J. Med. 170:156160.
42. Sarrazin, C.,, R. Rouzier,, F. Wagner,, N. Forestier,, D. Larrey,, S. K. Gupta,, M. Hussain,, A. Shah,, D. Cutler,, J. Zhang, and, S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:12701278.
43. Schneider, J.,, W. Halota,, D. Delic,, Z. Nesic,, D. Prokopowicz,, R. Flisiak,, J. Kuydowicz,, M. Jablkowski,, J. Cianciara,, T. Mach,, R. Modrzewska,, M. Fabri,, D. Tomic,, A. Horban,, W. Krycka, and, M. Cripps. 2006. A novel primboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: a phase IIa clinical trial. J. Clin. Virol. 36(Suppl. 2):S30. (Abstract.)
44. Sharma, P.,, V. Balan,, J. L. Hernandez,, A. M. Harper,, E. B. Edwards,, H. Rodriguez-Luna,, T. Byrne,, H. E. Vargas,, D. Mulligan,, J. Rakela, and, R. H. Wiesner. 2004. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 10:3641.
45. Shiffman, M. L. 1999. Improvement in liver histopathology associated with interferon therapy in patients with chronic hepatitis C. Viral Hepatol. Rev. 5:2743.
46. Sun, C. A.,, D. M. Wu,, C. C. Lin,, S. N. Lu,, S. L. You,, L. Y. Wang,, M. H. Wu, and, C. J. Chen. 2003. Incidence and co-factors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am. J. Epidemiol. 157:674682.
47. Reference deleted.
48. Wakita, T.,, T. Pietschmann,, T. Kato,, T. Date,, M. Miyamoto,, Z. Zhao,, K. Murthy,, A. Habermann,, H. G. Kräusslich,, M. Mizokami,, R. Bartenschlager, and, T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791796.
49. Wang, Z.,, Y. Tanaka,, Y. Huang,, F. Kirbanov,, J. Chen,, G. Zeng,, B. Zhou,, M. Mizokami, and, J. Hou. 2007. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J. Clin. Microbiol. 45:14911496.
50. Yang, H. I.,, S. N. Lu,, Y. F. Liaw,, S. L. You,, C. A. Sun,, L. Y. Wang,, C. K. Hsiao,, P. J. Chen,, D. S. Chen,, C. J. Chen, and Taiwan Community-Based Cancer Screening Project Group. 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347:168174.
51. Yang, S. H.,, C. G. Lee,, S. H. Park,, S. J. Im,, Y. M. Kim,, J. M. Son,, J. S. Wang,, S. K. Yoon,, M. K. Song,, A. Ambrozaitis,, N. Kharchenko,, Y. D. Yun,, C. M. Kim,, C. Y. Kim,, S. H. Lee,, B. M. Kim,, W. B. Kim, and, Y. C. Sung. 2006. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 13:11101117.
52. Yano, M.,, H. Kumada,, M. Kage,, K. Ikeda,, K. Shimamatsu,, O. Inoue,, E. Hashimoto,, J. H. Lefkowitch,, J. Ludwig, and, K. Okuda. 1996. The long-term pathological evolution of chronic hepatitis C. Hepatology 23:13341340.
53. Yuan, H. J.,, M. F. Yuen,, D. Ka-Ho Wong,, E. Sablon, and, C. L. Lai. 2005. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral Hepat. 12:373379.

Tables

Generic image for table
Table 1.

Responses to approved antiviral therapies among treatment-naive patients with HBeAg-positive CHB

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20
Generic image for table
Table 2.

Responses to approved antiviral therapies among treatment-naive patients with HBeAg-negative CHB

Citation: Sacchi P, Bruno R, Barbaro G, Barbarini G. 2009. Sequelae of Chronic Viral Hepatitis, p 371-388. In Fratamico P, Smith J, Brogden K (ed), Sequelae and Long-Term Consequences of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555815486.ch20

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error